Hyperviscosity Syndrome Follow-up

Updated: Dec 11, 2019
  • Author: Thomas J Hemingway, MD, FACEP; Chief Editor: Barry E Brenner, MD, PhD, FACEP  more...
  • Print

Further Inpatient Care

Supportive care should be initiated for the complications of hyperviscosity syndrome, pending definitive therapy. Complications to address may include blood loss, central nervous system disorders, cardiovascular effects, and metabolic derangements.

Note that the definitive treatment of hyperviscosity syndrome is treatment of the underlying disorder (eg, chemotherapy). If the underlying disease process is left untreated, the hyperviscosity will recur.



Consider transfer if hematology/oncology consultation and plasma or cellular pheresis are unavailable at the treating facility.



The prognosis in patients with hyperviscosity syndrome depends on the severity of the associated complications, and on the underlying cause of the syndrome and the response of the appropriate definitive treatment. For example, the long-term prognosis for patients with multiple myeloma continues to be poor.


Patient Education

See the list below:

  • The diseases leading to hyperviscosity are chronic, and this condition may recur.

  • Patients and their families and/or caregivers should be educated about early signs and symptoms (eg, bleeding, visual symptoms, headache, mental status changes, shortness of breath).